Celgene

This study tests a new medicine, BMS-986365, against two standard treatments (docetaxel or another hormone therapy) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to hormone therapy. About 960 participants will be random…

This study is testing a combination of two drugs, mezigdomide and elranatamab, in about 62 adults with multiple myeloma that has returned or no longer responds to standard treatments. The main goals are to find the safest dose and to see if the combination helps shrink or control…

This early-phase study tests two experimental drugs (iberdomide and CC-99282) added to standard chemotherapy (R-CHOP) for people with untreated aggressive B-cell lymphoma. About 224 adults will take part to find the safest dose and see if the combination helps shrink tumors. The …

This study tests a new drug combination (mezigdomide, bortezomib, and dexamethasone) against a standard combination (pomalidomide, bortezomib, and dexamethasone) in about 810 people with multiple myeloma that has returned or stopped responding to treatment. Participants must have…

This study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were in earlier luspatercept trials. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease …

This study tests whether a new drug called golcadomide combined with rituximab works better than standard treatments for people with follicular lymphoma that has returned or stopped responding to prior therapy. About 400 adults will be randomly assigned to either the new combo or…

This expanded access program provides a CAR T-cell therapy called ide-cel to people with multiple myeloma whose specially made treatment batch did not meet commercial standards. The goal is to offer a treatment option when no other suitable therapy is available. Participants must…

This study is testing a drug called luspatercept in children aged 6 to 18 with beta-thalassemia, a genetic blood disorder. Researchers want to find the safest and most effective dose and see if it can help children who need regular blood transfusions require fewer of them, or hel…

This study tests an experimental pill (BMS-986368) to see if it can safely reduce agitation in people with Alzheimer's disease. About 120 participants will receive either the drug or a placebo. The goal is to ease symptoms like restlessness and aggression, not to cure Alzheimer's…

This study tests an experimental oral medication (BMS-986368) to reduce muscle stiffness and spasms in people with multiple sclerosis. About 200 participants will receive one of three doses or a placebo. The main goal is to see if the drug improves muscle tightness and daily func…

This study follows children and adults who have already received gene-modified T cells in a previous trial. It does not give any new treatment but checks for long-term side effects, how long the modified cells last, and overall survival. The goal is to understand the lasting safe…

This study looks at how two other drugs (itraconazole and rifampin) change the amount of AR-LDD in the blood of healthy adult men. It involves 42 participants and is only for research, not treatment. The goal is to understand drug interactions for future use.